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Abstract
Background: During the past three decades, the incidence of hepatocellular carcinoma in the United States has
tripled. The neuroendocrine character has been observed in some tumor cells within some hepatocellular
carcinoma nodules and elevated serum chromogranin A also been reported in patients with hepatocellular
carcinoma. The aim of this work was to investigate the role of serum concentration of chromogranin A in patients
with hepatocellular carcinoma at different stages.
Methods: The study population consisted of 96 patients (63 males and 33 females age range 52-84) at their first
hospital admission for hepatocellular carcinoma. The control group consisted of 35 volunteers (20 males and 15
females age range 50-80). The hepatocellular carcinoma patients were stratified according the Barcelona-Clinic Liver
Cancer classification. Venous blood samples were collected before treatment from each patients before surgery,
centrifuged to obtain serum samples and stored at -80° C until assayed.
Results: The chromogranin A serum levels were elevated (> 100 ng/ml) in 72/96 patients with hepatocellular
carcinoma. The serum levels of chromogranin A were significantly correlated (p<0.05) with alpha-fetoprotein. In
comparison with controls, the hepatocellular carcinoma patients showed a significant increase (p<0.001) vs
controls. The chromogranin A levels in the Barcelona staging of hepatocellular carcinoma was higher in stage D
compared to stage C (p<0.01), to stage B (p<0.001), and to stage A (p<0.001).
Conclusions: Molecular markers, such as chromogranin A, could be very useful tools for hepatocellular carcinoma
diagnosis. However the molecular classification should be incorporated into a staging scheme, which effectively
separated patients into groups with homogeneous prognosis and response to treatment, and thus serves to aid in
the selection of appropriate therapy.
Background
During the past three decades, the incidence of hepatocel-
lular carcinoma (HCC) in the United States has tripled
with an annual increase of 4.5% [1]. Two diagnostic tests
are routinely used to detect HCC in clinical practice:
serum a-fetoprotein (AFP) and ultrasonography (US).
AFP is a glycoprotein, expressed during the early stages of
fetal liver development by the endodermal cells of the visc-
eral yolk sac, in the patients with testis cancer and during
hepatocarcinogenesis. The sensitivity of AFP as a diagnos-
tic tool is restricted by the existence of non-AFP-secreting
tumors [2-5]. The reliability of ultrasonographic diagnosis
depends on a range of factors, including the expertise of
the operator, the sophistication of the equipment and the
size and nature of the tumor. HCC commonly exhibits
histological polymorphism even within a single nodule.
The neuroendocrine character has been observed in some
tumor cells within some HCC nodules and elevated serum
chromogranin A (CgA) also been reported in patients with
HCC [6,7]. CgA is a member of the granin family of acidic
secretory glycoproteins that are expressed in all endocrine
and neuroendocrine cells, in various autoimmune disease,
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and correlated with the use of various drugs, such as pro-
ton pump inhibitors. CgA has been identified in numerous
variety of tumors, including bronchial [8], prostate [9],
pancreatic and gastrointestinal cancer [10,11]. The aim of
this work was to investigate the role of serum concentra-
tion of CgA in patients with HCC at different stages.
Methods
The study population consisted of 96 patients [63 males
and 33 females age range 52-84] at their first hospital
admission for HCC. The control group consisted of 35
volunteers [20 males and 15 females age range 50-80]. The
HCC patients were stratified according the Barcelona-
Clinic Liver Cancer classification (BCLC) [12-14]. The
BCLC staging classification links the stage of the disease
to a specific treatment strategy. The BCLC uses variables
related to tumour stage, liver functional status, physical
status, and cancer-related symptoms, thus linking the four
stages. The patients were recruited in a five years period
(1st January 2002- 31st December 2006) and their demo-
graphics and clinical characteristics are shown in table 1.
Venous blood samples were collected before treatment
from each patients before surgery, centrifuged to obtain
serum samples and stored at -80 °C until assayed. Clinical
chemistry tests were performed in the medical centre
laboratory using standard methods. Fasting blood samples
were taken at enrolment of the participants. Hepatitis B
surface antigen (HbsAg) and its antibody (HbcAb) and
antibody to delta antigen (anti-HDV) were all determined
by enzyme immunoassay (Abbott Laboratories, North Chi-
cago, IL). Antibody to hepatitis C virus (anti-HCV) was
assayed by a second-generation enzyme-linked immunoas-
say (ELISA, Ortho Diagnostixc Systems-Raritan, NJ).
Specific investigations included abdominal US and tripha-
sic spiral computerized tomography or magnetic reso-
nance (MR). A US-guided liver biopsy was performer
using a 18–21 range needle to sample both liver parench-
yma and focal lesion. A commercial solid phase two site
immunoradiometric assay was used to detect serum CgA
(CgA-RIA CT, CIS Biointernational ORIS Group, GIF-
SUR-Yvette, France). AFP was tested by using commer-
cially available immunometric assay (Architect AFP assay,
Abbott Laboratories, North Chicago, IL, USA). All data
are presented as mean ±S.D. Discrete and continuous vari-
ables were compared using either Student’s t-test or the
Wilcoxon Mann–Whitney non-parametric test for
unpaired data. Categorical variables were compared with
either the Chi square test or the Fisher exact test when
requested. The Spearman’s rank correlation coefficient
test was used to test for unvaried relationships between
variables. The applied tests were considered statistically
significant at p<0.05 level. Data were analyzed using the
statistical package SPSS for Windows 7.5 (SPSS Inc.,
Chicago, IL, USA).
Results and discussion
The CgA serum levels were elevated (> 100 ng/ml) in 72/
96 patients with HCC (Table 2). No significant differences
were found between males and females in either of the
groups. The serum levels of CgA were significantly corre-
lated (p<0.05) with AFP. In comparison with controls, the
HCC patients showed a significant increase (p<0.001)
compared to controls. The CgA levels in the Barcelona
staging of HCC was higher in stage D compared to stage
C (p<0.01), to stage B (p<0.001), and to stage A (p<0.001).
The most frequent site of neuroendocrine tumours is the
gastrointestinal tract, accounting for approximately 70%
[15] of the total neuroendocrine tumours in the body
[16,17]. Neuroendocrine tumours frequently metastasize
to the liver, but the liver itself seldom is the site of a pri-
mary tumour [18-20]. The etiology and histogenesis of
hepatic neuroendocrine tumours have remained elusive
and controversial [21]. Proposed theories on the origin of
neuroendocrine cells, that give rise to primary hepatic
neuroendocrine tumours, include ectopic neuroendocrine
cells of pancreatic or adrenal origin, neuroendocrine cells
from within the intraepatic biliary tree or from neuroen-
docrine-programmed ectoblasts [22]. The origin of neu-
roendocrine components in HCC can be explained by the
neuroendocrine cells existing in the original HCC tumour
Table 1 Demographic characteristics of subjects included in the study.
Parameter Stage 0 Stage A Stage B Stage C Stage D Controls
Number 15 21 19 24 17 35
Male\Female 10\5 15\6 10\9 17\7 11\6 20\15
Smokers yes\no 12\3 16\5 15\4 16\8 10\7 18\17
Heart rate b\m 78±6 84±5 77±8 88 ± 7 94 ± 7 78 ± 10
Systolic Pressure mmHg 135±10 144±12 141±13 140±12 145±10 136±10
Diastolic Pressure mmHg 84±8 88±10 85±9 87±8 88±9 84±7
HCV 6 7 9 10 10 -
HBV 5 8 8 8 4 -
Alcool 4 6 2 6 3 -
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as one of the histological components; or the occurrence
of phenotypic change and/ or differentiation of HCC cells;
a differentiation from hepatic stem cells [23]. HCC is a
complex neoplasm, in most cases on a background of pre-
neoplastic damaged liver. An hypothesis describes a step-
by-step process through which external stimuli could
induce genetic alterations in mature hepatocytes leading
to cell death and cellular proliferation. In the progression
of chronic inflammation to fibrosis and cirrhosis, the up-
regulation of mitogenic pathways leads to the production
of monoclonal populations. These populations harbour
dysplastic hepatocytes as a result of altered gene expres-
sion and telomerase erosions. Thus, molecular markers,
such as CgA, could be very useful tools for HCC diagnosis
[24]. However the molecular classification should be
incorporated into a staging scheme, which effectively sepa-
rated patients into groups with homogeneous prognosis
and response to treatment, and thus serves to aid in the
selection of appropriate therapy.
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